RNA sequencing data of Vemurafenib-resistant melanoma cells and parental cells

• Main Authors: Kun Zhao, Yanrong Lu, Younan Chen, Jingqiu Cheng, Wengeng Zhang
• Format: Article
• Language: English
• Published: Elsevier 2020-06-01
• Series: Data in Brief
• Subjects: Melanoma; BRAF; Vemurafenib; resistance; RNA-seq
• Online Access: http://www.sciencedirect.com/science/article/pii/S2352340920305047

Melanoma is a type of malignant tumor derived from melanocytes, most of which occur in the skin, and a few occur in the mucosa and choroid. BRAF mutations occur in approximately 50% of melanoma patients. Vemurafenib is a specific and potent BRAF inhibitor that significantly prolongs progression-free survival in patients with BRAF mutant melanoma. But most patients have tumor recurrence after 7-9 months. Drug resistance severely limits the long-term clinical effects of targeted drugs. To explore the mechanism of melanoma resistance to Vemurafenib, the transcripts of Vemurafenib-resistant melanoma A375R cells and the parental A375 cells were sequenced. For more insight please see Transcripts 202 and 205 of IL-6 confer resistance to Vemurafenib by reactivating the MAPK pathway in BRAF(V600E) mutant melanoma cells [1]. RNA-seq data has been uploaded to Sequence Read Archive (SRA), which allows researchers to obtain RNA sequence data for these cells.